Recent Advances in Single-Cell Profiling and Multispecific Therapeutics: Paving the Way for a New Era of Precision Medicine Targeting Cardiac Fibroblasts
| Autor: | Sally Yu Shi, Chi-Ming Li, Xin Luo, Brandon Ason, Tracy M. Yamawaki, Milena B. Furtado |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Single-cell RNA-sequencing
Cardiac fibrosis Cell Heart failure Computational biology 030204 cardiovascular system & hematology Multispecific therapeutics 03 medical and health sciences 0302 clinical medicine Cardiac fibroblast Response to injury medicine Humans Fibroblast 030304 developmental biology 0303 health sciences Cardiac fibroblasts business.industry Myocardium Precision medicine Regenerative Medicine (SM Wu Section Editor) Heart Fibroblasts medicine.disease Fibrosis medicine.anatomical_structure Biopharmaceutical Cardiology and Cardiovascular Medicine business |
| Zdroj: | Current Cardiology Reports |
| ISSN: | 1534-3170 1523-3782 |
| Popis: | Purpose of Review Cardiac fibroblast activation contributes to fibrosis, maladaptive remodeling and heart failure progression. This review summarizes the latest findings on cardiac fibroblast activation dynamics derived from single-cell transcriptomic analyses and discusses how this information may aid the development of new multispecific medicines. Recent Findings Advances in single-cell gene expression technologies have led to the discovery of distinct fibroblast subsets, some of which are more prevalent in diseased tissue and exhibit temporal changes in response to injury. In parallel to the rapid development of single-cell platforms, the advent of multispecific therapeutics is beginning to transform the biopharmaceutical landscape, paving the way for the selective targeting of diseased fibroblast subpopulations. Summary Insights gained from single-cell technologies reveal critical cardiac fibroblast subsets that play a pathogenic role in the progression of heart failure. Combined with the development of multispecific therapeutic agents that have enabled access to previously “undruggable” targets, we are entering a new era of precision medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink